Press releases

2009-11-10Orexo AB (publ) – Interim report January-September 2009
2009-10-16Nomination Committee prior to Orexo’s 2010 Annual General Meeting
2009-10-06Orexo confirms FDA acceptance of Abstral filing
2009-08-31New number of shares and votes in Orexo AB (publ)
2009-08-28Orexo signs exclusive worldwide license agreement for a novel formulation
2009-08-21Orexo AB (publ) – Interim report, January - June 2009
2009-08-18Orexo announces that its partner Meda has initiated the launch of EdluarTM in the USA
2009-08-06Abstral™ file submitted to the FDA for approval in the USA
2009-07-24Orexo announces positive Phase III results for KW-2246 in Japan
2009-06-30Orexo announces that Abstral is ready for launch in France
2009-05-06Orexo AB (publ.) – Interim report, January-March 2009
2009-04-23Report from Orexo AB’s Annual General Meeting, 23 April 2009
2009-04-06Orexo’s annual report for 2008 released
2009-03-25Notice of Annual General Meeting of Orexo AB, 23 April 2009
2009-03-24Orexo announces Phase IIa data on OX914 in rhinitis
2009-03-16Orexo’s Edluar (Sublinox) receives FDA approval for the treatment of insomnia
2009-03-02Orexo’s AbstralTM receives two further large EU market approvals in France and Spain
2009-02-27New number of shares and votes in Orexo AB (publ)
2009-02-23Orexo acquires a UK drug delivery company
2009-02-18Orexo signs agreement for Abstral in Israel
2009-02-17Orexo AB (publ) – Year-end Report January–December, 2008
2009-02-09Orexo signs an exclusive development agreement for its OX17 program
2009-01-27Orexo signs agreement for Abstral in China